

29 April 2026

Physiomics plc
("Physiomics" or the "Company")

Results of General Meeting and Board Changes

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that all resolutions ("**Resolutions**") put to shareholders at the general meeting, called by Mr Michael Whitlow, held today ("**General Meeting**") were passed.

As a result, Mr Michael Whitlow, Mr Ian Bagnall, and Mr Nicholas Tulloch have been appointed to the Board. In addition, Dr Peter Sargent, Mr Shalabh Kumar, and Dr Tim Corn, have been removed from the Board with immediate effect.

As previously stated, Dr Peter Sargent will remain as CEO (non-Board) of the Company until 29 May 2026. Furthermore, the outgoing directors have expressed their willingness to facilitate an orderly transition to the incoming directors.

Mr Michael Whitlow - Executive Director

Michael Whitlow is an entrepreneur with over 20 years' experience investing in and financing small cap and early-stage companies. Having started his career in the energy industry, Mr Whitlow has more recently overseen the assembly of a number of resource projects through Axies Ventures Ltd, including operational and corporate developments across the Mediterranean, North America and Australia.

Mr Nicholas Tulloch - Non-Executive Chair

Nicholas Tulloch has advised companies on the UK capital markets for over 20 years, having worked for a number of investment banks and stockbrokers, including Cazenove, Arbuthnot and Cenkos. He previously served as Financial Director and then CEO of Zoetic International plc (now Chill Brands Group plc), overseeing its transition from oil & gas to a CBD-focused quoted business. He subsequently founded Voyager Life plc and, in 2024, led Voyager Life plc's repositioning as Mendell Helium plc. Mr Tulloch is currently a director of Axies Ventures Ltd and re-joined Chill Brands Group plc as a non-executive director in 2024. Mr Tulloch began his career as a solicitor with Gouldens (now part of Jones Day) and holds a Master's degree in law from Oxford University.

Mr Ian Bagnall - Non-Executive Director

Ian Bagnall is a Chartered Accountant with over three decades of experience across corporate finance, operational leadership and investment management. He holds a BSc in Biochemistry and Physiology and qualified as a Chartered Accountant in 1990. Mr Bagnall has held senior finance roles across a number of businesses, including within the food sector, and later moved into operational leadership, serving as Managing Director of two food processing businesses. He subsequently held an Executive Board role with Pilgrim Foods, where he oversaw the Retail Division and was responsible for strategic development, commercial operations and business performance.

Further information regarding the appointments of Mr Whitlow, Mr Tulloch, and Mr Bagnall in accordance with paragraph (g) of Schedule Two of the AIM Rules for Companies (the "**AIM Rules**") is set out below.

Results of General Meeting

The results of the poll at the General Meeting are set out in the table below. Each Physiomics shareholder present in person or by proxy was entitled to one vote for each Physiomics share held.

Resolution	Votes for		Votes against		Total votes	Withheld votes
	Number	%	Number	%	Number	Number

1. That Nicholas Tulloch be appointed as a director of the Company with immediate effect.	177,819,776	77.94%	50,328,272	22.06%	228,148,048	3,867,652
2. That Michael Whitlow be appointed as a director of the Company with immediate effect.	177,508,328	77.91%	50,328,272	22.09%	227,836,600	4,179,100
3. That Ian Bagnall be appointed as a director of the Company with immediate effect.	177,508,328	77.80%	50,639,720	22.20%	228,148,048	3,867,652
4. Conditional on the passing of at least two of Resolutions 1, 2 or 3, that Dr Jim Millen be removed from office as a director of the Company with immediate effect.	179,586,226	77.41%	52,394,272	22.59%	231,980,498	35,202
5. Conditional on the passing of at least two of Resolutions 1, 2 or 3, that Shalabh Kumar be removed from office as a director of the Company with immediate effect.	179,274,778	78.04%	50,439,720	21.96%	229,714,498	2,301,202
6. Conditional on the passing of at least two of Resolutions 1, 2 or 3, that Dr Tim Corn be removed from office as a director of the Company with immediate effect.	177,707,733	77.89%	50,439,720	22.11%	228,147,453	3,868,247
7. Conditional on the passing of at least two of Resolutions 1, 2 or 3, that Dr Peter Sargent be removed from office as a director of the Company	175,276,136	76.74%	53,137,603	23.26%	228,413,739	3,601,961

with immediate effect.						
------------------------	--	--	--	--	--	--

Notes:

Any proxy votes which are at the discretion of the Chair have been included in the "Votes Against" total. Please note a vote "Withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

As at the date of the General Meeting, the total number of voting rights in the Company was 453,208,718.

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO
+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

Additional Information on the Appointment of the Directors:

Save for the information set out above and below, there are no further disclosures to be made in accordance with Rule 17 and Schedule Two paragraph(g) of the AIM Rules in respect of the appointments of the directors.

Nicholas George Selby Tulloch

The directorships and partnerships currently held by Nicholas Tulloch, aged 53, and over the five years preceding the date of his appointment are as follows:

Current Directorships

Mendell Helium plc

Past Directorships/Partnerships (within the last five years)

Orsus Therapeutics PLC

ECR Minerals plc	VoyagerCann Limited
M3 Helium Corporation	Orsus Labs Limited
Heartlands Industries Limited	Amphora Health Ltd
Fetlar Capital Limited	DG Innovate plc
Axies Ventures Ltd	U4EA plc
ECR Minerals (Australia) Pty Ltd	Chill Brands Group plc
ECR Minerals (Queensland) Pty Ltd	
ECR Digital Limited	
Mendell Digital LLC	
ECR Minerals (Raglan) Pty Ltd	

Nicholas Tulloch was a director between 10 April 2021 and 29 August 2024 at DG Innovate plc which appointed liquidators on 30 April 2025. The estimated total deficiency as regards to creditors is £3,668,556.

Michael Whitlow

The directorships and partnerships currently held by Michael Whitlow, aged 47, and over the five years preceding the date of his appointment are as follows:

Current Directorships

Volant Services (VSL) Limited
 Axies Ventures Ltd
 Holding365 Ltd

Past Directorships/Partnerships (within the last five years)

ECR Minerals plc

Ian Russell Bagnall

The directorships and partnerships currently held by Ian Bagnall, aged 61, and over the five years preceding the date of his appointment are as follows:

Current Directorships

The Maplesden Noakes School

Past Directorships (within the last 5 years)

Izzy Bizzy Ltd

Directors' shareholdings

Mr Whitlow holds a direct interest in the Company issued share capital totalling 56,000,000 ordinary shares, representing 12.36% of the Company's issued ordinary share capital.

Mr Bagnall holds a direct interest in the Company issued share capital totalling 15,000,000 ordinary shares, representing 3.31% of the Company's issued ordinary share capital.

Mr Tulloch does not hold a direct or indirect interest in the Company's issued share capital.